معرفی
David Cruz Hernandez is a Postdoctoral Scientist at the Vyas Group in the Radcliffe Department of Medicine, University of Oxford. His research focuses on the molecular mechanisms of differentiation arrest in myeloid cancers, particularly acute leukemias linked to Down syndrome. He utilizes gene editing, single-cell transcriptomics, and flow cytometry to study oncogenic cooperation between GATA1 mutations and trisomy 21.
- Education: B.A. in Chemistry, B.S. in Molecular and Cellular Biology, M.S. in Stem Cell Biology, DPhil in Medical Sciences.
His work explores how genetic and epigenetic changes in preleukemic states lead to leukemia, with a focus on identifying therapeutic targets like cytokine dependencies and JAK inhibition. Current projects analyze the role of RUNX1 deficiency and GATA1 isoforms in hematopoietic stem cell dysfunction.
Recent publications highlight his contributions to understanding the genetic basis of myeloid leukemias in Down syndrome, including studies on GATA1 mutations, IL-3 sensitivity, and the 5hmC epigenetic landscape. His research intersects hematology, cancer genetics, and developmental biology.
David is part of the Vyas Lab, which investigates human myeloid cancers and preleukemic states. He collaborates on modeling leukemia pathogenesis using primary cell cultures and CRISPR/Cas9 technologies.
